Us biotechnology company Moderna announced Monday that its experimental vaccine opposed to Covid-19 is 94. 5% effective, marking a breakthrough in the search for vaccines.
Moderna unveiled the first effects of a clinical trial with more than 30,000 participants, after US pharmaceutical company Pfizer and his German wife BioNTech said last week that their vaccine was 90% effective.
The two vaccine leaders are on a new platform called messenger RNA, which is faster to produce than classic vaccines and transforms human cells well into vaccine plants.
“This positive mid-term investigation of our Phase 3 exam gave us the first clinical validation that our vaccine can save you COVID-19 disease, adding serious illnesses,” said Stephane Bancel, Executive Director of Moderna.
The company plans to submit emergency approval programs in the US. But it’s not the first time And around the world in a matter of weeks and says it expects to have about 20 million doses in a position to be sent to the US. But it’s not the first time Until the end of the year.
Global infections caused by Covid-19 have surpassed 54 million, with more than 1. 3 million deaths since the virus gave the impression in China late last year.
The Modern vaccine, which evolved jointly through the US National Institutes of Health, has been jointly developed by the US National Institutes of Health. USA, it is administered in two doses 28 days apart, and the initial effects are based on 95 volunteers out of the 30,000 who have fallen ill with Covid-19.
Of the 95, 90 were in the placebo organization of the trial and in the organization that received the drug called mRN-1273.
The vaccine was well tolerated and most side effects were classified as mild or moderate.
After the first dose, approximately 3% of other people had pain in the injection classified as severe.
Among the effects classified as severe after the dose at the time, about 10% had fatigue, 9% had muscle pain, 5% had joint pain or headaches, 4% had other pain and 2% had redness at the injection site.
These adverse occasions were “short-lived,” according to one statement.
“This news from Moderna is incredibly exciting and greatly reinforces the optimism that we will have the selection of vaccines in the coming months,” said Peter Openshaw, Professor of Experimental Medicine at Imperial College London.
Most importantly, Moderna also announced that his vaccine may remain solid at refrigerator temperatures from 2 degrees Celsius to 8 degrees Celsius (36 degrees Fahrenheit at 46 degrees Fahrenheit) for 30 days.
The company added that it could be stored in a long-term garage at under-zero temperatures of -20 degrees Celsius (-4 degrees Fahrenheit) for six months.
The Pfizer vaccine, on the other hand, will have to be stored in freezing conditions, which can complicate the logistics of the chain of origin, especially in less evolved countries.
It is still known how long the opposite coverage will last for Modern or Pfizer vaccines or how well they work for the elderly, the maximum age organization at risk for Covid-19.
Get the latest news and research on issues from Nigeria, Africa and around the world, right in your inbox, every day.